Exclusive: Dupixent in a pill? Startup Insamo will try to turn blockbuster biologics into orals

A new biotech startup launched Wednesday to advance a “Goldilocks” therapeutic modality that could turn some of the industry’s most lucrative drugs into pills.

Berkeley, CA-headquartered Insamo was founded in 2022 by a trio of PhD scientists, who have raised a $12 million seed round that includes investors like venBio and Playground Global, CEO Tim Craven told Endpoints News exclusively. The board includes Playground’s venture partner Matt Hershenson and is chaired by venBio managing partner Corey Goodman.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Geneoscopy wins FDA approval for Labcorp-partnered colon cancer test

Dive Brief: Geneoscopy received Food and Drug Administration approval for its Colosense noninvasive colorectal cancer screening test, the company said Monday. The stool-based test, which

May 8, 2024

Unveiling brain sex differences with AI

A new study by Stanford Medicine investigators unveils a new artificial intelligence model that was more than 90% successful at determining whether scans of brain

February 20, 2024

GE Healthcare, Mass General Brigham Co-Develop AI Algorithm for Radiology Scheduling Predictions

What You Should Know: – GE HealthCare and Mass General Brigham form a strategic collaboration on the co-development of an artificial intelligence (AI) algorithm that

September 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.